8-K: Arcus Biosciences Reports Promising Interim Phase 1/1b Data for Casdatifan and Cabozantinib in Advanced Kidney Cancer

Arcus Biosciences, Inc. announced updated positive interim data from its Phase 1/1b ARC-20 study, highlighting a 46% confirmed objective response rate for casdatifan plus cabozantinib in patients with clear cell renal cell carcinoma who had progressed on prior immunotherapy.

Summary

• Arcus Biosciences, Inc. presented updated information regarding its portfolio and development programs, including interim data from the Phase 1/1b ARC-20 clinical trial.
• The ARC-20 study is evaluating once-daily 100mg of casdatifan combined with 60mg of cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) who had progressed on prior immunotherapy.
• The efficacy evaluable population included 24 patients who reached a minimum of 12 weeks follow-up or discontinued due to progression or adverse event, with a median follow-up of 5.3 months.
• The confirmed Objective Response Rate (cORR) per RECIST v1.1 was 46% (11 patients) with a 95% Confidence Interval of [26, 67].
• Best Overall Responses included 4% (1 patient) achieving a Complete Response, 42% (10 patients) achieving a Partial Response, 50% (12 patients) achieving Stable Disease, and 4% (1 patient) experiencing Progressive Disease.
• The safety evaluable population comprised 42 patients who received any amount of study drug and had at least one month of safety follow-up.
• No unexpected safety risks were identified, and the combination of casdatifan plus cabozantinib demonstrated an acceptable safety profile with no meaningful overlapping toxicity between the two drugs.

Sentiment

Score: 8

Explanation: The interim clinical data from the ARC-20 study is highly positive, demonstrating a promising objective response rate and an acceptable safety profile for casdatifan plus cabozantinib in a challenging patient population, which is a significant de-risking event for the program.

Positives

• A confirmed Objective Response Rate (cORR) of 46% was observed in the efficacy evaluable population, indicating significant tumor shrinkage in a substantial portion of patients.
• One patient (4%) achieved a Complete Response, which is a highly favorable outcome in cancer treatment.
• The combination therapy showed an acceptable safety profile with no unexpected safety risks identified.
• There was no meaningful overlapping toxicity between casdatifan and cabozantinib, suggesting the combination is well-tolerated.

Risks

• None explicitly mentioned in this specific filing beyond the inherent risks associated with clinical trials, which are not detailed as specific risks for this program.

Future Outlook

The document indicates that Arcus Biosciences continues to develop its portfolio and programs, with the updated data from the ARC-20 study supporting the ongoing development of casdatifan in combination with cabozantinib for clear cell renal cell carcinoma.

Management Comments

• "No unexpected safety risks were identified at the time of DCO, and casdatifan plus cabozantinib had an acceptable safety profile with no meaningful overlapping toxicity for the two drugs."

Industry Context

Clear cell renal cell carcinoma (ccRCC) represents a significant unmet medical need, particularly for patients who have progressed after prior immunotherapy. The development of novel combination therapies, such as casdatifan with the approved drug cabozantinib, is a common strategy in oncology to improve patient outcomes in difficult-to-treat populations. The reported data suggests a potentially effective new therapeutic approach in this challenging disease setting.

Comparison to Industry Standards

• A confirmed Objective Response Rate (ORR) of 46% in a Phase 1/1b study for previously treated clear cell renal cell carcinoma patients is generally considered promising, especially given the challenging nature of this patient population.
• The observation of a 4% Complete Response rate is a strong positive signal for an early-stage trial in this indication.
• The acceptable safety profile with no unexpected or overlapping toxicities is crucial for combination therapies and compares favorably to the toxicity profiles often seen with multi-agent regimens in oncology.

Stakeholder Impact

• Shareholders: The positive clinical data could lead to increased investor confidence and potentially a positive impact on the company's share price.
• Patients: The promising results offer hope for a new, effective treatment option for clear cell renal cell carcinoma patients who have progressed on prior immunotherapy.
• Healthcare Providers: The data suggests a potential new therapeutic combination that could be integrated into future treatment paradigms for ccRCC.

Next Steps

• Continued development of the casdatifan plus cabozantinib program for clear cell renal cell carcinoma.

Key Dates

Recommendation

Keywords

Arcus Biosciences, RCUS, casdatifan, cabozantinib, renal cell carcinoma, ccRCC, immunotherapy, clinical trial, Phase 1/1b, oncology, drug development, ARC-20, objective response rate, complete response, partial response, stable disease, safety profile